Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up

Journal of Neurology

Volumn 263, Issue 2, 2016, Pages 370-379

  Piccolo, L ^a,b   Woodhall, M ^c   Tackley, G ^a   Jurynczyk M ^a   Kong, Y ^d   Domingos, J ^a,e   Gore, R ^a   Vincent, A ^c   Waters, P ^c   Leite, M I ^a   Palace, J ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

AQP4 Ab; MOG Ab; Neuromyelitis optica; Optic neuritis; Visual loss

Indexed keywords

AQUAPORIN 4 ANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN G1; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; AUTOANTIBODY; AUTOANTIGEN; IMMUNOGLOBULIN G; MOG PROTEIN, HUMAN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ATYPICAL OPTIC NEURITIS; CONTRAST ENHANCEMENT; FEMALE; GENETIC ANALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; ONSET AGE; OPTIC NEURITIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SENSITIVITY AND SPECIFICITY; VISUAL ACUITY; ADOLESCENT; BLOOD; CHILD; IMMUNOLOGY; MIDDLE AGED; NEUROMYELITIS OPTICA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AQUAPORIN 4; AUTOANTIBODIES; AUTOANTIGENS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; OPTIC NEURITIS; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84957841095     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7983-1     Document Type: Article

References (34)

1. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4water channel. J Exp Med 202(4):473–477
3. Fujihara K, Misu T, Nakashima I et al (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3:58–73
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815
5. Jarius S, Frederikson J, Waters P et al (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1–2):158–162
6. Jacob A, McKeon A, Nakashima I et al (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 84(8):922–930
7. Arrambide G, Rovira A, Tur C, Montalban X (2014) NMO spectrum disorders: how wide is the spectrum? Mult Scler 20(10):1417–1419
8. Pittock SJ, Weinshenker BG, Lucchinetti CF et al (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63(7):964–968
9. Poppe AY, Lapierre Y, Melançon D et al (2005) Neuromyelitis optica with hypothalamic involvement. Mult Scler 11(5):617–621
10. Takahashi T, Fujihara K, Nakashima I et al (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130(pt 5):1235–1243
11. Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65(7):913–919
12. Waters PJ, McKeon A, Leite MI et al (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665–671 (discussion 669. 6)
13. Kitley J, Leite MI, Küker W et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 70(11):1375–1381
14. Pandit L, Asgari N, Apiwattanakul M et al (2015) Demographic and clinical features of neuromyelitis optica: a review. Multi Scler J 21(7):845–853 (Review)
15. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452
16. Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–1277
17. Waters P, Woodhall M, O’Connor KC et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2(3):e89
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489
19. Matiello M, Lennon VA, Jacob A et al (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70(23):2197–2200 (epub 2008 Apr 23)
20. Petzold A, Plant GT (2014) Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev 13(4–5):539–545 (epub 2014 Jan 12)
21. Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 115(6):1079–1082 (e5)
22. Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 261(1):17–26
23. Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834–1849
24. Reindl M, Di Pauli F, Rostásy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9(8):455–461 (Review)
25. O’Connor KC, McLaughlin KA, De Jager PL et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211–217
26. Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–1277
27. Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276–283
28. Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481
29. Ramanathan S, Reddel SW, Henderson A et al (2014) Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 1(4):e40
30. Martinez-Hernandez E, Sepulveda M, Rostásy K et al (2015) Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol 72(2):187–193
31. Brilot F, Dale RC, Selter RC et al (2009) Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66:833–842
32. Probstel AK, Dornmair K, Bittner R et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580–588
33. Baumann M, Sahin K, Lechner C et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr (epub 2014 Aug 13)
34. Höftberger R, Sepulveda M, Armangue T et al (2015) Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21(7):866–874